Literature DB >> 28238074

Atorvastatin-induced dermatomyositis.

Mert Oztas1, Serdal Ugurlu2, Ovgu Aydin3.   

Abstract

A 49-year-old man with no previous history of musculoskeletal or cutaneous problems who had a myocardial infarction (MI) was treated with atorvastatin, prasugrel, enoxaparine, and diltiazem following percutaneous coronary intervention. He was referred to our rheumatology outpatient clinic for rash and papules on the knuckles, face, and neck, as well as proximal muscle weakness. In the physical examination, a reddish rash on the face and Gottron's papules on the knuckles were detected. The skin biopsy performed indicated interface dermatitis with hydropic degeneration of basal keratinocytes, supporting the clinical impression of dermatomyositis. He was started on prednisolone 1 mg/kg/day. After 30 days of prednisolone therapy, all symptoms disappeared.

Entities:  

Keywords:  Atorvastatin; Dermatomyositis; Statin-induced dermatomyositis

Mesh:

Substances:

Year:  2017        PMID: 28238074     DOI: 10.1007/s00296-017-3658-9

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  10 in total

1.  Atorvastatin-induced dermatomyositis.

Authors:  B Noël; J P Cerottini; R G Panizzon
Journal:  Am J Med       Date:  2001-06-01       Impact factor: 4.965

2.  Statins and lupus erythematosus.

Authors:  B Noël
Journal:  Rheumatology (Oxford)       Date:  2004-03       Impact factor: 7.580

3.  Atorvastatin-induced dermatomyositis in a 47-year-old woman with Sjögren's syndrome.

Authors:  Eri Komai; Minoru Takemoto; Koutaro Yokote
Journal:  Acta Cardiol       Date:  2015-06       Impact factor: 1.718

Review 4.  Statin-Associated Autoimmune Myopathy.

Authors:  Andrew L Mammen
Journal:  N Engl J Med       Date:  2016-02-18       Impact factor: 91.245

5.  Statin-induced rhabdomyolysis and dermatomyositis: a rare combination.

Authors:  Cecilia S Cannon
Journal:  JAAPA       Date:  2012-08

Review 6.  Muscle-related side-effects of statins: from mechanisms to evidence-based solutions.

Authors:  Beth A Taylor; Paul D Thompson
Journal:  Curr Opin Lipidol       Date:  2015-06       Impact factor: 4.776

Review 7.  Statin safety: a systematic review.

Authors:  Malcolm Law; Alicja R Rudnicka
Journal:  Am J Cardiol       Date:  2006-02-03       Impact factor: 2.778

8.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

Authors: 
Journal:  Lancet       Date:  1994-11-19       Impact factor: 79.321

9.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

Authors:  J R Downs; M Clearfield; S Weis; E Whitney; D R Shapiro; P A Beere; A Langendorfer; E A Stein; W Kruyer; A M Gotto
Journal:  JAMA       Date:  1998-05-27       Impact factor: 56.272

10.  Immune-mediated necrotizing myopathy associated with statins.

Authors:  Phyllis Grable-Esposito; Hans D Katzberg; Steven A Greenberg; Jayashri Srinivasan; Jonathan Katz; Anthony A Amato
Journal:  Muscle Nerve       Date:  2010-02       Impact factor: 3.217

  10 in total
  3 in total

Review 1.  Lipid-lowering agent-triggered dermatomyositis and polymyositis: a case series and literature review.

Authors:  Isabela Bruna Pires Borges; Marilda Guimarães Silva; Rafael Giovane Misse; Samuel Katsuyuki Shinjo
Journal:  Rheumatol Int       Date:  2017-10-12       Impact factor: 2.631

2.  Aggressive and fatal statin-induced dermatomyositis: a case report.

Authors:  Raíssa Massaia Londero Chemello; Ana Maria Benvegnú; Lia Natália Diehl Dallazem; Diego Chemello
Journal:  Oxf Med Case Reports       Date:  2017-12-11

3.  Study on the differentially expressed genes and signaling pathways in dermatomyositis using integrated bioinformatics method.

Authors:  Wei Liu; Wen-Jia Zhao; Yuan-Hao Wu
Journal:  Medicine (Baltimore)       Date:  2020-08-21       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.